News tagged with tamiflu
Swine flu strain that is resistant to Tamiflu is spreading more easily
The flu season is still young in the United States and the rest of the Northern Hemisphere, but Australia wrapped up its flu season months ago, and public health officials there have some disturbing news to report: The version ...
Diseases, Conditions, Syndromes
Dec 29, 2011 |
5 / 5 (2) |
0
Tamiflu doesn't offer relief promised, study finds
For the nearly 62 million Americans infected with influenza each year, oeseltamivir, commonly called Tamiflu, promises to offer relief. New research from the University of Georgia finds the medication may not have all of ...
Medications
Oct 26, 2012 |
4 / 5 (2) |
1
|
CDC: Flu seems to level off except in the West
New government figures show that flu cases seem to be leveling off nationwide. Flu activity is declining in most regions although still rising in the West.
Diseases, Conditions, Syndromes
Jan 25, 2013 |
5 / 5 (1) |
0
Oseltamivir
Oseltamivir (INN) (pronounced /ɒsəlˈtæmɨvɪr/) is a drug that blocks the influenza virus from spreading between cells in the body. Thus it is an antiviral drug that is used in the treatment and prophylaxis of both Influenzavirus A and Influenzavirus B infection. Like zanamivir, oseltamivir is a neuraminidase inhibitor. It acts as a transition-state analogue inhibitor of influenza neuraminidase, preventing progeny virions from detaching from infected cells.
Oseltamivir was the first orally active neuraminidase inhibitor commercially developed. It is a prodrug, which is hydrolysed hepatically to the active metabolite, the free carboxylate of oseltamivir (GS4071). It was developed by US-based Gilead Sciences and is currently marketed by Hoffmann–La Roche (Roche) under the trade name Tamiflu. In Japan, it is marketed by Chugai Pharmaceutical Co., which is more than 50% owned by Roche. Oseltamivir is generally available by prescription only.
Roche estimates that 50 million people have been treated with oseltamivir. The majority of these have been in Japan, where an estimated 35 million have been treated. Since June 2009, Roche has been forced to allow other companies to develop competing drugs to Tamiflu, after much speculation about Roche's so-called 'monopoly' of Tamiflu in the UK.[citation needed]
For more information about Oseltamivir, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
